[{"StockholdersEquityConverted_0_Q1_USD":37673000000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":2236000000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":3824000000.0,"EarningsPerShareDiluted_1_Q1_USD":0.89,"StockholdersEquity_0_Q1_USD":37605000000.0,"NetIncomeLossConverted_1_Q1_USD":2029000000.0,"Assets_0_Q1_USD":112435000000.0,"CommonStockDividendsPerShareDeclared_1_Q1_USD":0.49,"RevenuesConverted_1_Q1_USD":11073000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":2265000000.0,"EarningsPerShareBasic_1_Q1_USD":0.9,"Ticker":"BMY","CIK":"14272","name":"BRISTOL MYERS SQUIBB CO","OfficialName":"Bristol-Myers Squibb Company Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"162365000000.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"SP500","filed":"20210429"}]